| Stereochemistry | ACHIRAL |
| Molecular Formula | C38H38N4O6 |
| Molecular Weight | 646.7315 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(CN(CCC3=CC=C(NC(=O)C4=C(NC(=O)C5=CN=C6C=CC=CC6=C5)C=C(OC)C(OC)=C4)C=C3)CC2)C=C1OC
InChI
InChIKey=LGGHDPFKSSRQNS-UHFFFAOYSA-N
InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43)
Tariquidar, a non-competitive, specific P-glycoprotein (Pgp) inhibitor, is an anthranilamide derivative with multidrug resistance properties. Tariquidar binds to the ATP-binding cassette (ABC) transport protein Pgp, thereby inhibiting transmembrane transport of anticancer drugs resulting in their increased intracellular concentrations augmenting cytotoxicity of an anticancer drug. Tariquidar was discovered by Xenova Group and was developed for the treatment of multidrug resistance in cancer. In October 2002 the US Food
and Drug Administration (FDA) has granted fast track review status to tariquidar for the treatment of multi-drug resistance in first-line treatment of non-small cell lung cancer (NSCLC) patients. Tariquidar is still undergoing research as an adjuvant against multidrug resistance in cancer.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Sample Use Guides
40 mg/m2 docetaxel over 1 hour on days 1 and 8 and 150 mg/m2 tariquidar over 30 minutes on days 8 and 22.
Route of Administration:
Intravenous
The effect of increasing concentrations of XR9576 (tariquidar) on the steady-state accumulation of [3H]-vinblastine (100 nm) and [3H]-paclitaxel (1 um) was measured in CHrB30 cells at 37°C. XR9576 (tariquidar) was shown to be a potent modulator of Pgp mediated [3H]-vinblastine and [3H]-paclitaxel transport as it increased the steady-state accumulation of these cytotoxics in the P-gp over-expressing CHrB30 cells with EC50 = 487+/-50 nM compared to non-Pgp-expressing AuxB1 cells.
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
